- Roivant will develop RVT-2001 for the treatment of transfusion-dependent anemia in patients with lower-risk myelodysplastic syndromes
- Roivant JPM presentation scheduled for Monday, January 10, at 2:15 p.m. ET
BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Jan. 05, 2022 (GLOBE NEWSWIRE) — Roivant Sciences (NASDAQ:ROIV), a next-generation biopharmaceutical company dedicated to improving the delivery of healthcare to patients, today announced that it has entered into a licensing agreement with Eisai Co., Ltd. for exclusive global rights to the investigational agent RVT-2001 (also known as H3B-8800), which will provide the lead program for a new subsidiary Vant.
RVT-2001 is an orally available small molecule modulator of splicing factor 3B subunit 1 (SF3B1) with over 80 human subjects exposed to date. Under the terms of the agreement, Eisai will receive an upfront payment, development and regulatory milestone payments, and royalties on sales revenue for RVT-2001.
Roivant plans to develop RVT-2001 as a first-in-class therapy for transfusion-dependent anemia in patients with lower-risk myelodysplastic syndromes (MDS). The company intends to conduct a robust open-label expansion of an ongoing clinical trial for RVT-2001 (ClinicalTrials.gov Identifier: NCT02841540) this year.
Additional details on RVT-2001 and the company’s development plan will be provided during Roivant’s presentation at the 40th Annual J.P. Morgan Healthcare Conference. The presentation by Roivant’s chief executive officer, Matthew Gline, is scheduled for Monday, Jan. 10, 2021, at 2:15 p.m. ET. A livestream of the presentation will be accessible from the “Events & Presentations” page of Roivant’s website at https://investor.roivant.com/news-events/events and an archived recording of the presentation will be available for 30 days.
